|
2026 Journal Article Oncologist and general practitioner perspectives of telehealth-delivered colorectal cancer survivorship careLisy, Karolina, Tieu, Matthew, Laing, Erin, Gore, Claire, Schofield, Penelope, Chan, Raymond J., Emery, Jon, Martin, Andrew, Lourenco, Richard De Abreu and Jefford, Michael (2026). Oncologist and general practitioner perspectives of telehealth-delivered colorectal cancer survivorship care. Psycho-Oncology, 35 (5) e70491. doi: 10.1002/pon.70491 |
|
2026 Journal Article Beyond Bloodstream Infection: The Potential for Hierarchical Composite Endpoints in Vascular Access ResearchMellander, Carl, Martin, Andrew J, Langan, Gaurav, Seifert, Stefanie, Hammarskjöld, Fredrik, Taxbro, Knut and Rickard, Claire M (2026). Beyond Bloodstream Infection: The Potential for Hierarchical Composite Endpoints in Vascular Access Research. Clinical Infectious Diseases ciag276. doi: 10.1093/cid/ciag276 |
|
2026 Journal Article Predictive value of early PSMA upregulation for the response to enzalutamide ± <SUP>177</SUP>Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trialEmmett, Louise, Swiha, Mina, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn, Goh, Jeffrey, Pattison, David, Pathmanandavel, Sarennya, Hope, Thomas, Ayati, Narjess, Hofman, Michael, Sandhu, Shahneen, Niu, Claire, Martin, Andrew, Thomas, Hayley, Stockler, Martin and Davis, Ian (2026). Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial. Nature Cancer, 7 (4), 622-630. doi: 10.1038/s43018-026-01140-3 |
|
2026 Journal Article Prognostic value of interim PSMA-PET total tumor volume for overall survival within ENZA-p, a randomized phase 2 trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901)Emmett, Louise, Papa, Nathan, Sartor, Oliver, Morris, Michael J., Subramaniam, Shalini, Crumbaker, Megan, Ayati, Narjess, Chen, Jeffrey, Herrmann, Ken, Gafita, Andrei, Swiha, Mina, Joshua, Anthony M., Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Ho, Bao, Khan, Sobia, Tan, Thean Hsiang, Bills, Madison, Nguyen, Andrew, Thein, Thida, Sidhom, George, Wong, Keith, Martin, Andrew James, Hofman, Michael S., Sandhu, Shahneen ... Davis, Ian D. (2026). Prognostic value of interim PSMA-PET total tumor volume for overall survival within ENZA-p, a randomized phase 2 trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901). European Urology. doi: 10.1016/j.eururo.2026.03.026 |
|
2026 Journal Article Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304)Inderjeeth, Andrisha-Jade, Martin, Andrew J., Zielinski, Robert R., Begbie, Stephen, Cheung, Leanna, Chowdhury, Simon, Frydenberg, Mark, Horvath, Lisa G., Joshua, Anthony M., Lawrence, Nicola J., Marx, Gavin, McCaffrey, John, McDermott, Raymond S., McJannett, Margaret, North, Scott A., Parnis, Francis, Parulekar, Wendy R., Pook, David W., Reaume, Martin N., Sandhu, Shahneen, Tan, Alvin, Tan, Thean H., Thomson, Alastair H., Vera-Badillo, Francisco, Williams, Scott G., Thomas, Hayley, Yip, Sonia, Zhang, Alison Y., Chi, Kim N. ... Davis, Ian D. (2026). Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304). European urology oncology, 9 (2), 396-403. doi: 10.1016/j.euo.2026.01.008 |
|
2026 Journal Article <sup>177</sup> Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate CancerAyati, Narjess, Papa, Nathan, Crumbaker, Megan, Subramaniam, Shalini, Joshua, Anthony M., Alipour, Ramin, Iravani, Amir, Askari, Emran, Khan, Sobia, Yadav, Surekha, Eiber, Matthias, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Nguyen, Andrew, Hofman, Michael S., Sandhu, Shahneen, Hioki, Takanori, van Oorschodt, Julian C. J., Devitt, Katrina, Willowson, Kathy, Sharma, Shikha, Stancu, Alexandru, Chauvie, Stephane ... on behalf of the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group (2026). 177 Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer. Radiology, 319 (1) e252672, e252672. doi: 10.1148/radiol.252672 |
|
2026 Journal Article Implementation science in hybrid randomized controlled trials: a state-of-the-art systematic reviewLiu, Mark G., Comber, Elouise, Martin, Andrew, Roberts, Natasha, Trott, Mike, Costa, Nathalia, Foster, Nadine E. and Hickman, Ingrid J. (2026). Implementation science in hybrid randomized controlled trials: a state-of-the-art systematic review. JBI Evidence Implementation. doi: 10.1097/xeb.0000000000000568 |
|
2026 Journal Article Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancerMunzur, Aslı D., Herberts, Cameron, Kwan, Edmond M., Emmett, Louise, Sandhu, Shahneen, Buteau, James P., Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Lee, Sze-Ting, Scott, Andrew M., Martin, Andrew J., Stockler, Martin R., Zhang, Alison Y., Williams, Scott G., Bernales, Cecily Q., Donnellan, Gráinne, Koudjanian, Melissa, Parekh, Karan, Bacon, Jack V. W., Karsan, Aly, Azad, Arun A., Davis, Ian D., Hofman, Michael S. and Wyatt, Alexander W. (2026). Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer. Clinical Cancer Research, OF1-OF9. doi: 10.1158/1078-0432.ccr-25-4001 |
|
2026 Journal Article Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin–naïve Non–muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301)Hayne, Dickon, Zhang, Alison Y., Thomas, Hayley, Krieger, Laurence, Ischia, Joseph, Anderson, Paul, Srivastav, Ratnesh K., Green, William, Grummet, Jeremy, Bastick, Patricia A., Beardsley, Emma K., Blatt, Alison, Patel, Manish, Chan, Lewis, Mitterdorfer, Andrew, Roberts, Matthew, Sengupta, Shomik, Winter, Matthew, Marx, Gavin, Bishop, Conrad, Cheung, Leanna, Hawks, Cynthia, Martin, Andrew, McCombie, Steve P., Redfern, Andrew D., Davis, Ian D. and Stockler, Martin R. (2026). Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin–naïve Non–muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). European Urology, 89 (5), 446-453. doi: 10.1016/j.eururo.2026.01.009 |
|
2026 Journal Article Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancerSoon, Yu Yang, Marschner, Ian C., Schou, I. Manjula, Sweeney, Christopher J., Davis, Ian D., Stockler, Martin R. and Martin, Andrew J. (2026). Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer. BJU International, 137 (1) bju.70065, 173-180. doi: 10.1111/bju.70065 |
|
2025 Journal Article Evaluating clinician sustainment of a Mediterranean‐style dietary pattern approach in routine care for coronary heart disease and type 2 diabetes utilizing Normalization MeAsure Development (NoMAD) instrumentMayr, Hannah L., Murray, Eryn, Maher, Patrick, Hayes, Lisa, Wang, William Y. S., Kelly, Jaimon T., Palmer, Michelle, Martin, Andrew and Hickman, Ingrid J. (2025). Evaluating clinician sustainment of a Mediterranean‐style dietary pattern approach in routine care for coronary heart disease and type 2 diabetes utilizing Normalization MeAsure Development (NoMAD) instrument. Nutrition in Clinical Practice, 40 (6) ncp.70055, 1552-1569. doi: 10.1002/ncp.70055 |
|
2025 Journal Article Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trialsMartin, Andrew J., Soon, Yu Yang, Sjoquist, Katrin Marie, Pavlakis, Nick, Goldstein, David, Shitara, Kohei and Simes, John R. (2025). Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trials. Gastric Cancer, 28 (6), 1252-1259. doi: 10.1007/s10120-025-01670-2 |
|
2025 Journal Article Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304)Lin, H.-M., Scheinberg, T., Portman, N., Kim, R.M.N., Mellor, R., Hunyh, K., Faulkner, A.N., Mellett, N.A., Davis, I.D., Martin, A., Sullivan, D., Joshua, A., McJannett, M., Subhash, V., Yip, S., Azad, A.A., Marschner, I.C., North, S.A., McDermott, R.S., Chi, K.N., Stockler, M.R., Sweeney, C.J., Meikle, P.J. and Horvath, L.G. (2025). Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304). Annals of Oncology, 36 (9), 1068-1077. doi: 10.1016/j.annonc.2025.05.529 |
|
2025 Journal Article Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Papa, Nathan, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Sandhu, Shahneen, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ayati, Narjess, Niu, Claire, Hofman, Michael S, Martin, Andrew James, Thomas, Hayley, Davis, Ian D, Stockler, Martin R and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2025). Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (9), 1168-1177. doi: 10.1016/S1470-2045(25)00339-0 |
|
2025 Journal Article INTEGRATE pooled phase II/III results are robust to post-progression switching and winner’s curseSoon, Yu Yang, Sjoquist, Katrin, Marschner, Ian C., Schou, I Manjula, Pavlakis, Nick, Goldstein, David, Shitara, Kohei, Stockler, Martin R., Simes, John and Martin, Andrew J. (2025). INTEGRATE pooled phase II/III results are robust to post-progression switching and winner’s curse. JNCI Cancer Spectrum, 9 (4) pkaf053, 1-7. doi: 10.1093/jncics/pkaf053 |
|
2025 Journal Article Oncologist and general practitioner perspectives of shared care for colorectal cancer survivors: A qualitative studyLisy, Karolina, Tieu, Matthew, Gore, Claire, Schofield, Penelope, Chan, Raymond J., Emery, Jon, Martin, Andrew, De Abreu Lourenco, Richard and Jefford, Michael (2025). Oncologist and general practitioner perspectives of shared care for colorectal cancer survivors: A qualitative study. Psycho-Oncology, 34 (7) e70223, 1-12. doi: 10.1002/pon.70223 |
|
2025 Journal Article Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trialKwan, Edmond M., Ng, Sarah W. S., Tolmeijer, Sofie H., Emmett, Louise, Sandhu, Shahneen, Buteau, James P., Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Subhash, Vinod, Lee, Sze-Ting, Scott, Andrew M., Martin, Andrew J., Stockler, Martin R., Donnellan, Grainne, Annala, Matti, Herberts, Cameron, Davis, Ian D., Hofman, Michael S., Azad, Arun A., Wyatt, Alexander W., Akhurst, Tim, Alipour, Ramin, Bailey, Dale L., Banks, Patricia, Beaulieu, Alexis, Campbell, Louise, Chua, Wei, Crumbaker, Megan ... on behalf of the TheraP Investigators and the ANZUP Cancer Trials Group (2025). Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. Nature Medicine, 2025 (8), 1-15. doi: 10.1038/s41591-025-03704-9 |
|
2025 Journal Article Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trialEmmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Joshua, Anthony M, Sandhu, Shahneen, Nguyen, Andrew, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Kumar, Aravind S Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick ... Bills, Madison (2025). Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. The Lancet Oncology, 26 (3), 291-299. doi: 10.1016/s1470-2045(25)00009-9 |
|
2025 Journal Article Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)Conduit, Ciara, Inderjeeth, Andrisha-Jade, Allen, Raymond, Martin, Andrew J., Parulekar, Wendy, Mulroe, Eibhlin, McJannett, Margaret, Zielinski, Robert R., Thomson, Alastair, Tan, Thean Hsiang, Sandhu, Shahneen K., Reaume, M. Neil, Pook, David W., North, Scott A., Marx, Gavin M., Joshua, Anthony, Horvath, Lisa, McDermott, Ray, Chowdhury, Simon, Chi, Kim N., Zhang, Alison Y., Stockler, Martin R., Davis, Ian D., Sweeney, Christopher J. and on behalf of ANZUP Cancer Trials Group (2025). Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304). Future Oncology, 21 (6), 627-636. doi: 10.1080/14796694.2024.2440277 |
|
2025 Journal Article Balancing precision and affordability in assessing infant development in large-scale mortality trials: Secondary analysis of a randomised controlled trialRobledo, Kristy P., Rieger, Ingrid, Finlayson, Sarah, Tarnow-Mordi, William and Martin, Andrew J. (2025). Balancing precision and affordability in assessing infant development in large-scale mortality trials: Secondary analysis of a randomised controlled trial. Archives of Disease in Childhood: Fetal and Neonatal Edition, 110 (4), F409-F414. doi: 10.1136/archdischild-2024-327762 |
